Treatment Approach for High-Grade Uterine Sarcoma

Introduction to Treatment

The standard treatment for high-grade uterine sarcoma is total abdominal hysterectomy followed by chemotherapy and/or radiation therapy based on disease stage, with systemic therapy being the cornerstone for advanced disease, as recommended by the National Comprehensive Cancer Network 1, 2

Total abdominal hysterectomy (TAH) is the standard primary treatment for all localized uterine sarcomas, according to the British Journal of Cancer 1, 2
Routine lymphadenectomy is not indicated as lymph node involvement is less than 5%, as stated by the British Journal of Cancer 1, 2
Complete surgical staging should include peritoneal lavage for cytology, omental and peritoneal biopsies, and maximal tumor debulking for gross disease, as recommended by the National Comprehensive Cancer Network 3

For stage I high-grade uterine sarcoma, observation alone is an option, or consideration of adjuvant chemotherapy (category 2B recommendation) may be given, as suggested by the National Comprehensive Cancer Network 4, 5
For stage II-III disease, chemotherapy and/or tumor-directed radiation therapy is recommended, with multimodality therapy typically recommended for these aggressive tumors, according to the National Comprehensive Cancer Network 3, 4, 5

For high-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma, treatment parallels that for adult-type soft tissue sarcomas, with recommended chemotherapy regimens including carboplatin/paclitaxel, as stated by the National Comprehensive Cancer Network 3, 6
For carcinosarcomas, ifosfamide/paclitaxel (category 1 recommendation) is recommended, with carboplatin/paclitaxel also being effective, as suggested by the National Comprehensive Cancer Network 3, 6

Hormone receptor testing should be performed, as approximately 50% of uterine leiomyosarcomas express estrogen and progesterone receptors, according to the British Journal of Cancer 1, 2
For hormone receptor-positive tumors, hormonal therapy may be considered, particularly for recurrent disease, as recommended by the National Comprehensive Cancer Network 4, 5

Systemic therapy is the mainstay for recurrent disease, with consideration of surgical resection for isolated metastases, as stated by the National Comprehensive Cancer Network and Annals of Oncology 4, 5, 7
For hormone receptor-positive recurrent disease, consider hormonal agents such as aromatase inhibitors, as suggested by the National Comprehensive Cancer Network 4, 5

High-grade sarcoma patients should be followed every 3-4 months in the first 2-3 years, then twice a year up to the fifth year and once a year thereafter, with regular chest X-rays or CT scans to detect pulmonary metastases, as recommended by Annals of Oncology 7